Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico

The study evaluated the incremental cost-effectiveness ratio (ICER) of the prophylaxis of palivizumab, for the reduction of complications associated to the respiratory syncytial virus in preterm patients in Mexico. Material and Methods. A decision tree was developed in preterm groups [<29 and 29-...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Salud Pública de México
Main Authors: Guillermo Salinas-Escudero, Silvia Martínez-Valverde, Alfonso Reyes-López, Juan Garduño-Espinosa, Onofre Muñoz-Hernández, Víctor Granados-García, Kely Rely
Formato: Artigo
Idioma:Inglês
Publicado: Instituto Nacional de Salud Pública 2012
Assuntos:
Salud
QALY
Mexico
antibodies
monoclonal
Cost effectiveness
Acceso en liña:https://www.redalyc.org/articulo.oa?id=10623032007
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares